Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 1548 (111th)

Pathway for Biosimilars Act

referredUnited States· United States Congress· EN

Introduced

17 March 2009

Last action

18 March 2009 · Referred

Status

Referred to the Subcommittee on Health.

Sponsors

Rep. Eshoo, Anna G. [D-CA-18], Rep. Inslee, Jay [D-WA-1], Rep. Barton, Joe [R-TX-6], Rep. Green, Gene [D-TX-29], Sen. Baldwin, Tammy [D-WI], Rep. Rogers, Mike J. [R-MI-8], Rep. Bono, Mary [R-CA-44], Rep. Hill, Baron P. [D-IN-9], Rep. Upton, Fred [R-MI-6], Rep. Barrow, John [D-GA-12], Rep. Pitts, Joseph R. [R-PA-16], Rep. Thompson, Mike [D-CA-4], Rep. Capuano, Michael E. [D-MA-8], Rep. Davis, Susan A. [D-CA-53], Rep. Bilbray, Brian P. [R-CA-50], Rep. Dreier, David [R-CA-26], Rep. Ellsworth, Brad [D-IN-8], Rep. McGovern, James P. [D-MA-2], Rep. Herger, Wally [R-CA-2], Rep. Dent, Charles W. [R-PA-15], Rep. Gerlach, Jim [R-PA-6], Rep. Bishop, Timothy H. [D-NY-1], Rep. Lofgren, Zoe [D-CA-18], Rep. Pence, Mike [R-IN-6], Rep. Souder, Mark E. [R-IN-3], Rep. Honda, Michael M. [D-CA-15], Rep. Tauscher, Ellen O. [D-CA-10], Rep. Scalise, Steve [R-LA-1], Rep. Towns, Edolphus [D-NY-10], Rep. Crowley, Joseph [D-NY-14], Rep. Issa, Darrell [R-CA-48], Rep. Murphy, Patrick J. [D-PA-8], Rep. Bean, Melissa L. [D-IL-8], Rep. Delahunt, William D. [D-MA-10], Rep. Smith, Adam [D-WA-9], Rep. McCarthy, Kevin [R-CA-22], Rep. Neal, Richard E. [D-MA-1], Rep. Lynch, Stephen F. [D-MA-8], Sen. Donnelly, Joe [D-IN], Rep. Hall, Ralph M. [R-TX-4], Rep. Lance, Leonard [R-NJ-7], Rep. Holt, Rush [D-NJ-12], Rep. Nunes, Devin [R-CA-22], Rep. Kind, Ron [D-WI-3], Rep. Sullivan, John [R-OK-1], Rep. Carney, Christopher P. [D-PA-10], Rep. Fattah, Chaka [D-PA-2], Rep. Holden, Tim [D-PA-17]

Subjects

Healthcare

Source updated

14 August 2025

Healthcare

Official sourceDownload fileView documentsShare

Summary

Pathway for Biosimilars Act - Amends the Public Health Service Act to allow a person to submit an application for licensure of a biological product based on its similarity to a licensed biological product (the reference product). Requires the Secretary of Health and Human Services to approve the application if: (1) the biological product is biosimilar to the reference product with respect to each condition of use for which the reference product is approved; and (2) the applicant consents to the inspection of the facility that is the subject of the application. Sets forth requirements for a determination by the Secretary that a biological product is interchangeable with a reference product. Prohibits a biological product from being evaluated against more than one reference product. Prohibits licensure under this Act of a biological product containing specified agents or toxins or a schedule I or II controlled substance unless the Secretary determines there would be no increased risk to the security or health of the public from licensing such a biological product. Prohibits the Secretary from making approval of an application under this Act effective until 12 yeas after the date on which the reference product was first licensed. Provides for confidentiality of information received pursuant to this Act. Sets forth provisions governing patent infringement actions related to this Act. Deems as patent infringement the submission of a statement under this Act by the applicant setting forth reasons why the making, use, or sale of the biosimilar product would not infringe the patent, or why the patent is invalid or unenforceable, if the purpose of such submission is to obtain approval to engage in the commercial manufacture, use, or sale before the expiration of such patent.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 17 March 2009

    Introduced

    Referred to House Energy and Commerce

    Source: IntroReferral

  2. 17 March 2009

    Introduced

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Source: IntroReferral

  3. 17 March 2009

    Introduced

    Sponsor introductory remarks on measure. (CR E687-688)

    Source: IntroReferral

  4. 17 March 2009

    Introduced

    Introduced in House

    Source: IntroReferral

  5. 17 March 2009

    Introduced

    Introduced in House

    Source: IntroReferral

  6. 18 March 2009

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 17 March 2009

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 17 March 2009

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 17 March 2009

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Showing 48 of 152 sponsors and actors.

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.